<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02332408</url>
  </required_header>
  <id_info>
    <org_study_id>HRVH-COI-03</org_study_id>
    <nct_id>NCT02332408</nct_id>
  </id_info>
  <brief_title>CyberKnife Based Hypofractionated Radiotherapy for Vertebral Hemangiomas</brief_title>
  <acronym>CKHRTVH</acronym>
  <official_title>CyberKnife Based Hypofractionated Radiotherapy Versus Conventional Linac Based Radiotherapy for Painful Vertebral Hemangiomas - Controlled Randomized Clinical Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Maria Sklodowska-Curie Institute - Oncology Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Maria Sklodowska-Curie Institute - Oncology Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Clinical objective of the study is to compare the analgesic effect, toxicity and pathologic
      effect in the tumors of two radiotherapy schedules used for patients suffering from painful
      vertebral haemangiomas
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Hemangiomas are frequent vertebral lesions (12% of the whole human population) but only 1%
      displays any clinical symptoms . The most common symptom is local pain, usually non
      responding for non-steroid anti-inflammatory drugs. Radiation therapy usually does not result
      calcification or the tumor regression, but significantly reduces the pain intensity or
      eliminates it. Currently, the most common RT schedule is conventional radiotherapy using
      fraction dose (fd) of 2 Gy delivered to the total dose (TD) varying from36 Gy to 40 Gy. The
      results in pain reduction achieved after larger total doses are better that led us to use
      radioablative techniques. This procedure is associated with a probability of better analgesic
      effect and the good local effect (calcification and / or regression of laesion) with high
      safety of radiation delivery using tracking based cybernetic microradiosurgery (CyberKnife).

      The comparison of two modalities of radiation therapy (conventional [fd 2 Gy, TD 36 Gy] and
      hypofractionated [fd 5 Gy, TD 25 Gy]) used for treatment of painful vertebral hemangioma
      patients will be performed in the phase III randomized study.

      80 patients will be enrolled in this study. All patients will be planned (RT) on the base of
      CT/MRI fusion.

      Patients will be controlled 1, 3, 6, 9, 12 months after treatment completion and, next every
      each 6 months. Pain relief, analgesics uptake, local effect (MRI and Technetium -
      99m-labelled RBC(red blood cell) scintigraphy) and eventual toxicity will be checked during
      follow-up (FU).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2014</start_date>
  <completion_date type="Anticipated">September 2021</completion_date>
  <primary_completion_date type="Anticipated">September 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Analgetic effect</measure>
    <time_frame>2 years</time_frame>
    <description>rate of pain relief</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Identification of radiologic prognostic and predictal factors of response to external beam radiotherapy (radiosurgery compared to conventional)</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Identification of biochemical and physical prognostic factors of response to external beam radiotherapy (radiosurgery compared to conventional)</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Hemangioma of Vertebral Column</condition>
  <arm_group>
    <arm_group_label>Cybernetic microradiosurgery</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Hypofractionated microradiosurgery using Cyber Knife to the vertebral hemangioma to the total dose of 25 Gy in 5.0 Gy per fraction, 2 or 3 days a week over the period of 2 weeks,</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Conventional radiotherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Conventionally fractionated external beam conformal radiotherapy to the vertebral hemangioma to the total dose of 36 Gy in 2.0 Gy per fraction, 5 days a week over the period of 3,5 weeks,</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Cybernetic microradiosurgery</intervention_name>
    <description>Cybernetic microradiosurgery (6MV) using tracking to TD 25Gy given in five fraction (5Gy p fr) two or three days a week, during 2 weeks</description>
    <arm_group_label>Cybernetic microradiosurgery</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Conventional radiotherapy</intervention_name>
    <description>Conventionally fractionated linac based external beam radiation therapy - EBRT, (conformal or dynamic) to the TD of 36 Gy, in 2.0 Gy per fraction 5 days a week over the period of 3.5 weeks)</description>
    <arm_group_label>Conventional radiotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Confirmed vertebral hemangioma ,

          2. Lesion visible in CT and MR

          3. Pain located in area of the lesion

          4. Informed consent for participation in the study and for radiotherapy in interested
             area

        Exclusion Criteria:

          1. Any previous radiotherapy in region of treated hemangioma

          2. Spinal damage or disease that may be associated with an increased radiosensitivity

          3. The coexistence of the vertebral morphological changes at the level of hemangioma
             causing pressure on the nerve roots and / or spinal cord causing pain located in that
             area

          4. Neurological deficits caused by the presence of hemangioma (patients should be
             considered for surgery)

          5. Contradictions for MRI

          6. Lack of informed consent.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Leszek Miszczyk, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Gliwice Branch, Gliwice, Poland</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Leszek Miszczyk, MD, PhD</last_name>
    <phone>0048322788001</phone>
    <email>leszek@io.gliwice.pl</email>
  </overall_contact>
  <location>
    <facility>
      <name>Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology Gliwice Branch</name>
      <address>
        <city>Gliwice</city>
        <state>Wybrzeze AK 15</state>
        <zip>44-100</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Leszek MIszczyk, MD. PhD</last_name>
      <phone>+48322788001</phone>
      <email>leszek@io.gliwice.pl</email>
    </contact>
    <investigator>
      <last_name>Leszek Miszczyk, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Grzegorz Wozniak, MD PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Aleksandra Napieralska, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Andrzej Tukiendorf, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>MIchał Gola, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Michał Kalemba, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Poland</country>
  </location_countries>
  <reference>
    <citation>Sakata K, Hareyama M, Oouchi A, Sido M, Nagakura H, Tamakawa M, Akiba H, Morita K. Radiotherapy of vertebral hemangiomas. Acta Oncol. 1997;36(7):719-24.</citation>
    <PMID>9490090</PMID>
  </reference>
  <reference>
    <citation>BARTKOWIAK E, BEDNARCZYK J. [CAVERNOUS ANGIOMA OF THE SPINE COMPLICATED BY COMPRESSION VERTEBRAL FRACTURE]. Chir Narzadow Ruchu Ortop Pol. 1964;29:393-6. Polish.</citation>
    <PMID>14191260</PMID>
  </reference>
  <reference>
    <citation>Bremnes RM, Hauge HN, Sagsveen R. Radiotherapy in the treatment of symptomatic vertebral hemangiomas: technical case report. Neurosurgery. 1996 Nov;39(5):1054-8. Review.</citation>
    <PMID>8905767</PMID>
  </reference>
  <reference>
    <citation>Heyd R, Seegenschmiedt MH, Rades D, Winkler C, Eich HT, Bruns F, Gosheger G, Willich N, Micke O; German Cooperative Group on Radiotherapy for Benign Diseases. Radiotherapy for symptomatic vertebral hemangiomas: results of a multicenter study and literature review. Int J Radiat Oncol Biol Phys. 2010 May 1;77(1):217-25. doi: 10.1016/j.ijrobp.2009.04.055. Epub 2009 Aug 21. Review.</citation>
    <PMID>19699592</PMID>
  </reference>
  <reference>
    <citation>Asthana AK, Tandon SC, Pant GC, Srivastava A, Pradhan S. Radiation therapy for symptomatic vertebral haemangioma. Clin Oncol (R Coll Radiol). 1990 May;2(3):159-62.</citation>
    <PMID>2261405</PMID>
  </reference>
  <reference>
    <citation>Brackrock S, Krüll A, Schwarz R, Alberti W. [Results of radiotherapy for vertebral hemangioma]. Strahlenther Onkol. 1999 Aug;175(8):405-8. German.</citation>
    <PMID>10481773</PMID>
  </reference>
  <reference>
    <citation>Faria SL, Schlupp WR, Chiminazzo H Jr. Radiotherapy in the treatment of vertebral hemangiomas. Int J Radiat Oncol Biol Phys. 1985 Feb;11(2):387-90.</citation>
    <PMID>3972655</PMID>
  </reference>
  <reference>
    <citation>Miszczyk L, Ficek K, Trela K, Spindel J. The efficacy of radiotherapy for vertebral hemangiomas. Neoplasma. 2001;48(1):82-4.</citation>
    <PMID>11327544</PMID>
  </reference>
  <reference>
    <citation>Pavlovitch JM, Nguyen JP, Djindjian M, Mazeron JJ, Piedbois P, Le Bourgeois JP. [Radiotherapy of vertebral hemangioma with neurologic complications]. Neurochirurgie. 1989;35(5):296-8, 305-8. French.</citation>
    <PMID>2630926</PMID>
  </reference>
  <reference>
    <citation>Rades D, Bajrovic A, Alberti W, Rudat V. Is there a dose-effect relationship for the treatment of symptomatic vertebral hemangioma? Int J Radiat Oncol Biol Phys. 2003 Jan 1;55(1):178-81.</citation>
    <PMID>12504051</PMID>
  </reference>
  <reference>
    <citation>Schild SE, Buskirk SJ, Frick LM, Cupps RE. Radiotherapy for large symptomatic hemangiomas. Int J Radiat Oncol Biol Phys. 1991 Aug;21(3):729-35.</citation>
    <PMID>1869466</PMID>
  </reference>
  <reference>
    <citation>Winkler C, Dornfeld S, Baumann M, Christen N, Herrmann T, Eberhardt HJ. [The efficacy of radiotherapy in vertebral hemangiomas]. Strahlenther Onkol. 1996 Dec;172(12):681-4. German.</citation>
    <PMID>8992637</PMID>
  </reference>
  <reference>
    <citation>Yang ZY, Zhang LJ, Chen ZX, Hu HY. Hemangioma of the vertebral column. A report on twenty-three patients with special reference to functional recovery after radiation therapy. Acta Radiol Oncol. 1985 Mar-Apr;24(2):129-32.</citation>
    <PMID>2988274</PMID>
  </reference>
  <reference>
    <citation>Miszczyk L, Tukiendorf A. Radiotherapy of painful vertebral hemangiomas: the single center retrospective analysis of 137 cases. Int J Radiat Oncol Biol Phys. 2012 Feb 1;82(2):e173-80. doi: 10.1016/j.ijrobp.2011.04.028. Epub 2011 Jun 2.</citation>
    <PMID>21640516</PMID>
  </reference>
  <reference>
    <citation>Gerszten PC, Ozhasoglu C, Burton SA, Vogel WJ, Atkins BA, Kalnicki S, Welch WC. CyberKnife frameless single-fraction stereotactic radiosurgery for benign tumors of the spine. Neurosurg Focus. 2003 May 15;14(5):e16.</citation>
    <PMID>15669812</PMID>
  </reference>
  <reference>
    <citation>Sahgal A, Chou D, Ames C, Ma L, Lamborn K, Huang K, Chuang C, Aiken A, Petti P, Weinstein P, Larson D. Image-guided robotic stereotactic body radiotherapy for benign spinal tumors: theUniversity of California San Francisco preliminary experience. Technol Cancer Res Treat. 2007 Dec;6(6):595-604.</citation>
    <PMID>17994789</PMID>
  </reference>
  <verification_date>January 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 4, 2015</study_first_submitted>
  <study_first_submitted_qc>January 4, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 6, 2015</study_first_posted>
  <last_update_submitted>January 4, 2015</last_update_submitted>
  <last_update_submitted_qc>January 4, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 6, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>vertebral hemangioma</keyword>
  <keyword>conventional radiotherapy</keyword>
  <keyword>Cyber Knife radiotherapy</keyword>
  <keyword>randomized trial</keyword>
  <keyword>radioablation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemangioma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

